Sign in to continue:

Tuesday, July 28th, 2026

英科再生资源2025年限制性股票激励计划部分限制性股票回购注销法律意见书

英科再生资源股份有限公司2025年限制性股票激励计划部分限制性股票回购注销实施法律意见书解读

英科再生资源股份有限公司2025年限制性股票激励计划部分限制性股票回购注销实施——法律意见书详细解读

要点概览

  • 英科再生资源股份有限公司(以下简称“英科再生”或“公司”)将对2025年限制性股票激励计划中部分限制性股票进行回购注销。
  • 本次回购注销涉及471,000股,回购价格为11.79元/股,资金来源为公司自有资金。
  • 回购注销原因主要为47名激励对象因个人原因离职,不再符合激励资格。
  • 本次回购注销已完成必要的董事会、股东会决策及债权人公告程序,未收到债权人异议。
  • 预计回购注销的限制性股票将在2026年7月29日完成注销,公司后续将依法办理工商变更登记。
  • 公司需履行信息披露及注册资本减少等相关法定程序。

投资者需关注的重要信息

  • 股份总数减少:本次回购注销将导致公司总股本减少471,000股,属于公司注册资本减少行为,可能对每股收益、每股净资产等指标带来正向影响。
  • 限制性股票激励对象异动:47名激励对象因个人原因离职,显示公司激励计划人员调整,或反映管理层流动性。
  • 回购价格与资金安排:回购价格为11.79元/股,均由公司自有资金支付,不涉及外部融资,不会对公司现金流造成重大压力。
  • 法定程序合规性:本次回购注销已完成所有必要董事会、股东会及债权人公告程序,且未收到债权人异议,合规性高。
  • 后续事项:公司需完成注销后工商变更登记及相关信息披露,股东需关注后续公告。
  • 潜在价格影响:股份回购注销通常会提升每股指标,理论上对股价有正面影响。但需关注激励对象流失是否对公司管理团队稳定性带来影响。

详细解读

英科再生于2025年5月29日召开董事会,审议并通过了2025年限制性股票激励计划相关议案。随后于2025年6月16日召开的股东会通过了相关授权。2026年4月27日,公司董事会审议决定调整限制性股票回购价格,并同意回购注销部分限制性股票。同年5月20日,公司发布了相关公告并依法通知债权人。截止法律意见书出具日,公告公示期已满45天,未收到任何债权人异议或清偿要求。

本次回购注销的主要原因系47名激励对象因个人原因离职,不再满足激励条件。依据激励计划,公司将对这些已获授但未解除限售的限制性股票按授予价格加同期银行定存利息进行回购注销。本次涉及的限制性股票总数为471,000股,回购价格为11.79元/股。资金来源为公司自有资金。

公司已在中国证券登记结算有限责任公司上海分公司开设回购专用证券账户,并申请办理回购注销手续。预计本次回购注销将在2026年7月29日前完成注销,后续公司将依法办理工商变更登记。

法律意见书结论认为,公司本次回购注销取得了现阶段所有必要的批准与授权,符合《公司法》《上市公司股权激励管理办法》和公司激励计划的相关规定。相关回购注销事项亦符合法律法规,尚需履行信息披露及注册资本减少等后续法定程序。

结论与投资者建议

本次限制性股票回购注销涉及股份数量较大,直接减少公司总股本,从而有望提升每股收益和每股净资产等指标,对公司二级市场股价可能形成支撑。同时,公司自有资金回购显示财务稳健,不会造成流动性风险。然而,需关注激励对象大规模离职可能对公司管理团队、核心员工稳定性带来的潜在影响。建议投资者持续关注公司后续公告及管理层结构变化。


免责声明:本文基于公开法律意见书解读,仅供投资参考,不构成任何投资建议。投资有风险,决策需谨慎。内容如有疑义,请以公司正式公告及法律文件为准。

Detailed Analysis of INCOME Renewable Resources Co., Ltd. 2025 Restricted Stock Incentive Plan Partial Share Buyback and Cancellation—Legal Opinion

Key Highlights

  • INCOME Renewable Resources Co., Ltd. (“the Company”) will repurchase and cancel part of the restricted shares under the 2025 Restricted Stock Incentive Plan.
  • The buyback involves 471,000 shares at a price of RMB 11.79 per share, funded entirely by the company’s own funds.
  • The main reason is that 47 incentive recipients resigned for personal reasons and no longer meet the incentive eligibility.
  • All necessary board, shareholder, and creditor notification procedures have been completed with no objections received.
  • The cancellation of restricted shares is expected to be completed by July 29, 2026, followed by business registration changes.
  • The company must fulfill information disclosure and statutory capital reduction procedures.

Key Issues for Investors and Shareholders

  • Reduction in Total Shares: The buyback and cancellation will reduce total share capital by 471,000 shares, which may positively impact per-share financial indicators.
  • Changes to Incentive Recipients: The departure of 47 recipients may reflect management or workforce changes.
  • Buyback Price and Funding: The price is RMB 11.79/share, paid from internal funds, with no impact on company liquidity.
  • Compliance: All legal processes have been properly completed with no creditor objections.
  • Follow-up Actions: Investors should watch for subsequent disclosures and business registration changes.
  • Potential Price Impact: Share buybacks generally improve per-share indicators and may support the stock price, but the impact of staff turnover should be noted.

In-Depth Summary

On May 29, 2025, the Board approved the 2025 Restricted Stock Incentive Plan, with subsequent shareholder approval on June 16, 2025. On April 27, 2026, the Board agreed to adjust the buyback price and approve the share cancellation. A creditor notification was issued on May 20, 2026, with no objections or claims received within 45 days.

The buyback is triggered by the resignation of 47 incentive recipients. In accordance with the plan terms, restricted shares not yet vested are repurchased at the grant price plus bank interest. A total of 471,000 shares are involved, at RMB 11.79 each, funded from company reserves.

A special account at China Securities Depository and Clearing Shanghai Branch has been opened for the buyback, and procedures for cancellation are underway, expected to conclude by July 29, 2026. Business registration changes will follow.

The legal opinion finds all necessary approvals and compliance are in place, matching regulatory requirements. Capital reduction and disclosure steps remain to be completed.

Conclusion and Investor Outlook

This share buyback and cancellation reduces company share capital, which could enhance EPS and NAV per share, potentially benefiting share price. The use of self-owned funds shows financial strength. However, the loss of incentive recipients may signal management changes. Investors should monitor company disclosures and management stability.


Disclaimer: This article is a summary and interpretation of a public legal opinion and is for informational purposes only. It does not constitute investment advice. Investing involves risks. Please rely on official company disclosures for decision making.


View 英科再生 Historical chart here



通策医疗股份有限公司宣布2026年股份回购进展及金额情况公告

通策医疗股份有限公司发布股份回购进展公告,或对股价产生积极影响 关键要点概述 回购方案首次披露日期:2026年6月4日...

CITIC Securities Announces Indirect Subsidiary CSI MTN Limited Issues USD 13.3 Million Medium-Term Notes with Full Guarantee by Subsidiary 1

中信证券股份有限公司关于间接子公司发行中期票据并由全资子公司提供担保的公告 主要内容及投资者关注点 发行与担保结...

河南太龙药业为子公司提供担保,累计担保总额达3.44亿元—2026年最新公告

河南太龙药业股份有限公司为下属子公司融资提供担保的详细公告解读 河南太龙药业股份有限公司为下属子公司融资提供担保的公...